Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abbvie, adulterated, aerosol, agonist, air, Alexza, alfa, Alkem, Allergan, alprazolam, annum, Apokyn, apomorphine, artificially, assembled, assembly, Aurobindo, avoid, Batycky, bioavailability, biomarker, bloodstream, breakdown, built, Burwell, cancelled, carbidopa, certified, Chelsea, cimaglermin, clearance, closure, Coalition, collateral, Colorado, column, Computershare, contrast, conventional, Corregidor, counterfeit, CRL, CVT, cyber, decarboxylase, deep, Deferral, denial, Depomed, desirable, desired, discharge, dopa, dopamine, doubt, dry, drying, dumping, Duopa, earliest, emission, episode, escalation, escrow, feature, filer, finite, FL, footnote, fundamental, gastric, gastrointestinal, GlaxoSmithKline, GMP, goodwill, greatest, hae, Head, hedge, Hindman, housed, hybrid, Hyouk, IDE, illegitimate, Impax, implanted, indenture, Inhalation, inhaled, inhaler, inhibitor, intentionally, inter, interlocutory, intestinal, intestine, intrusion, invasion, invasive, IPR, IRB, landlord, leadership, Lee, levodopa, lieu, MA, main, malware, MannKind, migraine, mimic, mobility, molding, Morgan, NeuroDerm, newest, Northern, occupied, oppose, overlease, par, Parkinson, PD, permission, pioneer, PMA, poll, postmarket, powder, pramipexole, premarket, promptly, pronouncement, provisional, PSWD, Pulmatrix, pulmonary, QD, QP, quarantine, quarantined, rank, raw, rebuilt, recommission, reconsider, redeem, redeemed, redemption, refinance, remediation, remedy, representation, reprioritization, reprioritized, restitution, restructuring, retired, revalidate, Rick, room, rotigotine, Roxane, RYTARY, satisfactorily, semiannually, sensitivity, Shareholder, Sinemet, sophisticated, sound, spin, SRS, stolen, strictly, sublease, subleased, sublingual, subordinated, Subtopic, surgically, surrendered, suspect, suspected, temperature, tongue, tremor, triptan, Trust, trustee, tube, undergone, underwriter, underwriting, underwritten, unfit, unreliable, unsecured, unsettled, USA, Valeant, Vectura, Vice, vulnerable, warranty, water, week, Wilmington, workforce
Removed:
accidental, acetonitrile, Aetna, afforded, altered, Amerisource, AMT, aspect, Australia, Biovest, bottle, buprenophine, chloride, chloroform, CP, dehydrated, depletion, distinct, empty, enabled, environment, ether, ethyl, exploitation, faith, formaldehyde, functional, Glial, glycol, hazard, implementation, improperly, irrevocable, isopropanol, ketamine, lesion, MAA, magnesium, Master, matter, methanol, monoclonal, musculoskeletal, pentobarbital, polyethylene, polymer, prevail, promoted, recalled, reclassified, recordkeeping, reformulation, rejected, remit, replacing, restoring, resume, rigorously, ruling, Separation, sodium, sponsorship, stabilized, sufficiently, TBI, tolerable, umbrella, unavailability, undiscounted, vest, vested, Wessel, xylene, Zealand
Filing tables
Filing exhibits
- 10-K Annual report
- 10.31 Stock Option Certificate
- 10.32 Restricted Stock Agreement
- 10.36 Lease Agreement
- 10.37 First Lease Amendment
- 10.38 Second Lease Amendment
- 10.39 Sublease
- 10.75 Asset Purchase Agreement
- 10.76 First Apa Amendment
- 10.77 Second Apa Amendment
- 21 List of Subsidiaries
- 23 E&y Consent
- 31.1 CEO Certification
- 31.2 CFO Certification
- 32.1 CEO Certification
- 32.2 CFO Certification
- Download Excel data file
- View Excel data file
Related press release
ACORQ similar filings
Filing view
External links
Exhibit 23
Consent of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders of Acorda Therapeutics, Inc.:
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-196803) |
(2) | Registration Statement (Form S-8 Nos. 333-194375, 333-164626, 333-158085, 333-131846, 333-149726, 333-174785, 333-179906, and 333-187091) |
of our reports dated February 27, 2015 with respect to the consolidated financial statements of Acorda Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Acorda Therapeutics, Inc. included in this Annual Report (Form 10-K) of Acorda Therapeutics, Inc. for the year ended December 31, 2014 filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
MetroPark, New Jersey
February 27, 2015